Amsterdam Molecular Therapeutics

Amsterdam Molecular Therapeutics closes EUR 22 million equity financing

Published in Lab Business Week, November 12th, 2006

Amsterdam Molecular Therapeutics BV (AMT) announced the closing of its EUR 22 million private placement financing (series A round) with four top tier venture capital firms, ABN AMRO Capital/Life Sciences (AACLS), Advent Venture Partners (Advent Ventures), Gilde Healthcare Partners and CrEUR dit Agricole Private Equity.

AACLS led the financing.

AMT has a pipeline of gene therapies in clinical and preclinical development. The new funds will be used to take the clinical development of AMT's lead product AMT-011, to treat lipoprotein lipase deficiency, from phase II through to registration. Additionally, the funds will allow the company to accelerate its...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2006-11-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry

Search our medical news database